Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects
Abstract
(57) Summary book invention generally relates to the composite and method containing トラマドール and opioid antagonists for decrease of reinforcement of the painkilling effect of トラマドール, and/or one or more adverse action. Adverse action includes the harmful side effects in nausea, vomiting, a feeling of giddiness, headache, stillness (傾眠), or humans like itchiness. The present invention relates to the composite and method of reinforcing the stillness effect of トラマドール alternatively and decreasing the body dependence and/or the tolerance effect relevant to anti-痛覚脱失症, hyperalgesia, sensitive 興奮症, and トラマドール medication simultaneously. The method of the present invention reinforces the painkilling effect of トラマドール of the amount of painkilling, or the amount of semi- painkilling, and トラマドール on a 験-ed object, and on it And anti-痛覚脱失症, The process of prescribing the excitability opioid receptor antagonist (for example, naltrexone or ナルメフェン) of a certain quantity effective for decreasing the body dependence and/or the tolerance effect of hyperalgesia, sensitive 興奮症, and トラマドール for the patient is included.
Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
94 members in 9 offices
Priority claims1
| Document | Office | Kind | Date |
|---|---|---|---|
| 30616499 | United States of America | A |
Members94
| Document | Office | Kind | |
|---|---|---|---|
| CA2145207A1 | Canada | A1 | |
| WO9406426A1 | World Intellectual Property Organization (WIPO) | A1 | |
| CA2143210A1 | Canada | A1 | |
| WO9411752A1 | World Intellectual Property Organization (WIPO) | A1 | |
| IL107620D0 | Israel | D0 | |
| CA2168262A1 | Canada | A1 | |
| WO9503804A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU7474194A | Australia | A | |
| US5410313A | United States of America | A | |
| EP0668764A1 | European Patent Office (EPO) | A1 | |
| EP0670047A1 | European Patent Office (EPO) | A1 | |
| US5472943A | United States of America | A | |
| CA2195122A1 | Canada | A1 | |
| WO9602251A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU3276995A | Australia | A | |
| US5512578A | United States of America | A | |
| JPH08504189A | Japan | A | |
| IL107620A | Israel | A | |
| EP0711167A1 | European Patent Office (EPO) | A1 | |
| US5580876A | United States of America | A | |
| US5585348A | United States of America | A | |
| US5604202A | United States of America | A | |
| JPH09504267A | Japan | A | |
| US5624932A | United States of America | A | |
| US5633259A | United States of America | A | |
| EP0808165A1 | European Patent Office (EPO) | A1 | |
| EP0670047B1 | European Patent Office (EPO) | B1 | |
| DE69317298D1 | Germany | D1 | |
| AU691515B2 | Australia | B2 | |
| US5767125A | United States of America | A | |
| JPH10507740A | Japan | A | |
| DE69317298T2 | Germany | T2 | |
| AU4113599A | Australia | A | |
| AU4739999A | Australia | A | |
| EP0808165A4 | European Patent Office (EPO) | A4 | |
| EP0711167A4 | European Patent Office (EPO) | A4 | |
| US6011004A | United States of America | A | |
| USRE36547E | United States of America | E | |
| US6096756A | United States of America | A | |
| CA2373348A1 | Canada | A1 | |
| WO0067739A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU4992800A | Australia | A | |
| WO0067739A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US2001006967A1 | United States of America | A1 | |
| CA2408098A1 | Canada | A1 | |
| CA2408106A1 | Canada | A1 | |
| WO0185150A2 | World Intellectual Property Organization (WIPO) | A2 | |
| WO0185257A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU5945801A | Australia | A | |
| AU5956001A | Australia | A | |
| EP1178803A2 | European Patent Office (EPO) | A2 | |
| US6362194B1 | United States of America | B1 | |
| CA2427330A1 | Canada | A1 | |
| WO0241884A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU3942702A | Australia | A | |
| WO0185257A3 | World Intellectual Property Organization (WIPO) | A3 | |
| AU4242202A | Australia | A | |
| US2002094947A1 | United States of America | A1 | |
| WO0185150A3 | World Intellectual Property Organization (WIPO) | A3 | |
| JP2002544160A | Japan | A | |
| EP1280529A2 | European Patent Office (EPO) | A2 | |
| EP1284736A2 | European Patent Office (EPO) | A2 | |
| US2003073713A1 | United States of America | A1 | |
| US2003148941A1 | United States of America | A1 | |
| WO0241884A8 | World Intellectual Property Organization (WIPO) | A8 | |
| US2003232744A1 | United States of America | A1 | |
| JP2004501094A | Japan | A | |
| US2004024004A1 | United States of America | A1 | |
| EP1392265A2 | European Patent Office (EPO) | A2 | |
| JP2004515455A | Japan | A | |
| US6765010B2 | United States of America | B2 | |
| JP2004528273A | Japan | A | |
| CA2143210C | Canada | C | |
| EP1527778A1 | European Patent Office (EPO) | A1 | |
| AU782475B2 | Australia | B2 | |
| AU782533B2 | Australia | B2 | |
| US2005181974A1 | United States of America | A1 | |
| EP1600160A1 | European Patent Office (EPO) | A1 | |
| US2006052389A1 | United States of America | A1 | |
| US7026329B2 | United States of America | B2 | |
| US7034036B2 | United States of America | B2 | |
| AU2001259458B2 | Australia | B2 | |
| AU2001259560B2 | Australia | B2 | |
| US2007054932A1 | United States of America | A1 | |
| EP1178803B1 | European Patent Office (EPO) | B1 | |
| AT388707TThis record | Austria | T | |
| ATE388707T1 | Austria | T1 | |
| DE60038290D1 | Germany | D1 | |
| EP1600160B1 | European Patent Office (EPO) | B1 | |
| AT414515T | Austria | T | |
| ATE414515T1 | Austria | T1 | |
| DE69535890D1 | Germany | D1 | |
| JP2009062376A | Japan | A | |
| US2009203722A1 | United States of America | A1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| Ceased as to paragraph 5 lit. 3 law introducing patent treatiesCeasedRER | RER |
Numbers
- Application
- 932162
Titles2
- German
- OPIOIDANTAGONISTHALTIGE ZUSAMMENSETZUNG ZUR ERHÖHUNG DER ANALGETISCHEN WIRKSAMKEIT VON TRAMADOL UND VERRINGERUNG VON IHRE NEBENWIRKUNGEN
- English
- OPIOIDANT AGONIC COMPOSITION FOR INCREASING THE ANALGETIC EFFICACY OF TRAMADOL AND REDUCING THEIR SIDE EFFECTS
Classification
- CPC, 8
- A61K31/485
- A61K31/00
- A61K38/33
- G01N33/94
- A61P25/04
- G01N33/9486
- A61P43/00
- G01N2500/10
- IPC, 8
- A61K31 00
- A61K31 137
- A61K31 485
- A61K38 33
- A61K45 00
- A61P25 04
- A61P43 00
- G01N33 94